Retatrutide and NAD+: What the Studies Actually Tested
Compare the retatrutide phase 2, TRIUMPH-1 and TRIUMPH-2 trials with the NAD+ infusion pilot by population, outcome and follow-up. None tested the combination.
FormBlends Editorial Research · Updated 2026-10-04
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
Direct answer: The studies compared here tested retatrutide and NAD+ infusion separately. They establish findings about retatrutide-associated weight change and short-term NAD+ metabolism. They did not test whether adding NAD+ improves retatrutide results.
Retatrutide and NAD+: compare what was actually tested
| Study | Participants and comparison | Follow-up and measured outcome | Relevance to the combination question |
|---|---|---|---|
| Retatrutide Phase 2, 2023; PMID 37366315 | 338 adults with obesity or overweight; retatrutide versus placebo | Body-weight change, with primary assessment at 24 weeks and further results at 48 weeks | Tests retatrutide. There was no retatrutide-plus-NAD+ comparison group. |
| TRIUMPH-1 Phase 3, published September 2026; PMID 42814954 | 2,339 adults with obesity without diabetes; weekly retatrutide versus placebo | 80 weeks; weight change and outcomes in knee osteoarthritis and sleep-apnea subgroups | The published treatment-regimen estimate for weight change was -25.0% in the 12-mg group versus -3.9% with placebo. That finding does not measure an NAD+ add-on effect. |
| TRIUMPH-2 Phase 3, published September 29, 2026; PMID 42810372 | 1,152 adults with type 2 diabetes and overweight or obesity; retatrutide versus placebo | 80 weeks; body weight, glycemic outcomes and adverse events | Tests retatrutide without an NAD+ intervention; it does not estimate a combination effect. |
| Grant et al. NAD+ infusion pilot, 2019; PMID 31572171 | 11 men: eight received NAD+ infusion and three received saline | Six-hour infusion; plasma and urine samples through eight hours | Measures NAD+ and related metabolites. It was not an obesity weight-loss trial and did not include retatrutide. |
Why the mechanisms do not answer the clinical question
Retatrutide engages hormone receptors involved in metabolic regulation. NAD+ is a cellular cofactor, and the infusion pilot studied its metabolic handling. Those are different observations. A shared connection to metabolism does not turn the two studies into evidence for a combined intervention.
The distinction matters when a page promises more energy, faster weight loss or better tolerability from adding NAD+. The cited pilot measured metabolites over hours, while the retatrutide trials measured clinical outcomes over months. Neither design measured the proposed improvement from adding NAD+.
What a useful add-on comparison would need to measure
An informative study would compare otherwise similar retatrutide treatment with and without the specific NAD+ intervention. It would keep background treatment, follow-up and outcome definitions consistent, then report the difference between groups. Comparing a retatrutide result from one population with an NAD+ biomarker from another cannot isolate an add-on effect.
For a claimed weight-loss benefit, look for a between-group weight result. For a claimed fatigue benefit, look for a defined fatigue measure. For a tolerability claim, look for measured treatment discontinuations or adverse events. A change in NAD+ metabolites answers a biochemical question, not all three clinical questions.
Evidence context
Different receptor targets can suggest a hypothesis, but they do not establish that combining substances improves outcomes or is safe. Retatrutide activates GIP, GLP-1 and glucagon receptors. That description does not establish a safe combination with another peptide, prescription medicine or supplement.
A useful combination study would specify the actual products, participant population, comparator, clinical outcomes and adverse events. Evidence for each ingredient separately, animal experiments, or a plausible biological explanation is not evidence for the combined regimen in people. The sources cited here do not establish the combination raised by this page as an approved treatment.
Absence of a reported interaction is not proof that no interaction exists. These research limitations do not support instructions about spacing medicines, changing another prescription, stacking peptides or selecting a combination dose.